Trial Outcomes & Findings for Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration (NCT NCT05914311)

NCT ID: NCT05914311

Last Updated: 2026-06-09

Results Overview

Migration distance of trial leads anchored with Dermabond and suture versus suture alone will be measured by change in trial lead position as measured in millimeters when comparing initial x-ray after placement versus x-ray taken at lead removal 5-8 days after placement

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

57 participants

Primary outcome timeframe

From Baseline through Day 8

Results posted on

2026-06-09

Participant Flow

Unit of analysis: SCS Leads

Participant milestones

Participant milestones
Measure
All Participants
Each participant will have one of the 2 trial leads secured with both dermabond and suture-randomized to left or right. This study will be a controlled trial of the two standard of care methods of securing SCS leads in which the trial leads (left and right) will be secured with one lead being secured with a suture only while the second lead will be secured after placement with both a suture in addition to Dermabond. The patient will serve as their own control.
Overall Study
STARTED
57 2
Overall Study
Suture Only
57 1
Overall Study
Suture and Dermabond
57 1
Overall Study
COMPLETED
48 2
Overall Study
NOT COMPLETED
9 0

Reasons for withdrawal

Reasons for withdrawal
Measure
All Participants
Each participant will have one of the 2 trial leads secured with both dermabond and suture-randomized to left or right. This study will be a controlled trial of the two standard of care methods of securing SCS leads in which the trial leads (left and right) will be secured with one lead being secured with a suture only while the second lead will be secured after placement with both a suture in addition to Dermabond. The patient will serve as their own control.
Overall Study
procedure cancelled
2
Overall Study
missing images
7

Baseline Characteristics

Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Participants
n=57 Participants
Each participant will have one of the 2 trial leads secured with both dermabond and suture-randomized to left or right
Age, Continuous
66.9 years
STANDARD_DEVIATION 12.8 • n=20 Participants
Sex: Female, Male
Female
28 Participants
n=20 Participants
Sex: Female, Male
Male
29 Participants
n=20 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=20 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
56 Participants
n=20 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=20 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=20 Participants
Race (NIH/OMB)
Asian
0 Participants
n=20 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=20 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=20 Participants
Race (NIH/OMB)
White
56 Participants
n=20 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=20 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=20 Participants

PRIMARY outcome

Timeframe: From Baseline through Day 8

Migration distance of trial leads anchored with Dermabond and suture versus suture alone will be measured by change in trial lead position as measured in millimeters when comparing initial x-ray after placement versus x-ray taken at lead removal 5-8 days after placement

Outcome measures

Outcome measures
Measure
Suture Group
n=48 Participants
secure one of the 2 trial leads with suture only-randomized to left or right Suture: secures SCS trial leads with a suture
Dermabond
n=48 Participants
secure one of the 2 trial leads to be secured with both dermabond and suture-randomized to left or right Suture: secures SCS trial leads with a suture Dermabond: secures SCS trial leads with dermabond
Migration Distance of Trial Leads
10.6 mm
Standard Deviation 18.2
9.1 mm
Standard Deviation 18.2

SECONDARY outcome

Timeframe: Day 8

Population: 3 participants did not complete their survey. Each participant received one lead secured with suture only and a second lead secured with both suture and Dermabond. The patient served as their own control.

Patient satisfaction score will be valued on a 0-10 scale, with 0-not satisfied at all up to 10-greatest level of satisfaction. The survey asked general questions about participant satisfaction with the spinal cord stimulator (SCS) trial experience (overall satisfaction with experience), not about participant satisfaction with the Dermabond or suture fixation interventions separately.

Outcome measures

Outcome measures
Measure
Suture Group
n=45 Participants
secure one of the 2 trial leads with suture only-randomized to left or right Suture: secures SCS trial leads with a suture
Dermabond
secure one of the 2 trial leads to be secured with both dermabond and suture-randomized to left or right Suture: secures SCS trial leads with a suture Dermabond: secures SCS trial leads with dermabond
Patient Satisfaction Score
7.386 score on a scale
Standard Deviation 2.058

SECONDARY outcome

Timeframe: Day 8

percent of participants with a higher rate of infection

Outcome measures

Outcome measures
Measure
Suture Group
n=48 Participants
secure one of the 2 trial leads with suture only-randomized to left or right Suture: secures SCS trial leads with a suture
Dermabond
n=48 Participants
secure one of the 2 trial leads to be secured with both dermabond and suture-randomized to left or right Suture: secures SCS trial leads with a suture Dermabond: secures SCS trial leads with dermabond
Rate of Infection
0 percent of participants
0 percent of participants

SECONDARY outcome

Timeframe: Day 8

Number of patients who received pain relief from the spinal cord stimulation trial. Number of responders to the prognostic lead placements defined as \>50% pain relief over the length of the trial.

Outcome measures

Outcome measures
Measure
Suture Group
n=48 Participants
secure one of the 2 trial leads with suture only-randomized to left or right Suture: secures SCS trial leads with a suture
Dermabond
n=48 Participants
secure one of the 2 trial leads to be secured with both dermabond and suture-randomized to left or right Suture: secures SCS trial leads with a suture Dermabond: secures SCS trial leads with dermabond
Number of Patients With Pain Relief
48 participants
48 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Day 8

Difference in lead position on prone (face down) fluoroscopy vs upright (standing) x-ray

Outcome measures

Outcome data not reported

Adverse Events

All Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Carlyle Hamsher, MD

Atrium Health Wake Forest Baptist

Phone: 336-716-4498

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place